Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 24, 2020 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
August 19, 2020 07:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib, Provides Regulatory Update

ROS1+ TKI-Naïve Non-Small Cell Lung Cancer Confirmed Objective Response Rate is 86 Percent ROS1+ TKI-Pretreated Non-Small Cell Lung Cancer with One Prior TKI and Prior Chemotherapy, Confirmed...
August 10, 2020 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third Quarter Four Clinical Studies of Three Drug Candidates Ongoing; Early...
July 27, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
July 13, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer

SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
July 07, 2020 07:30 ET | Source: Turning Point Therapeutics, Inc.; Zai Lab

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China

Zai Lab Granted Exclusive Rights to Develop and Commercialize Repotrectinib in Greater China Turning Point to Receive $25 Million Upfront, Potential for Future Milestones of up to $151 Million and...
June 22, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
June 01, 2020 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
May 29, 2020 08:10 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
May 27, 2020 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...